Short communication
Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer
More details
Hide details
Submission date: 2011-10-19
Final revision date: 2011-12-08
Acceptance date: 2011-12-14
Online publication date: 2013-08-12
Publication date: 2014-02-20
Arch Med Sci 2014;10(1):149-153
Introductions: Phospho-PRAS40MThr246 (phosphorylated proline-rich Akt substrate of 40 kilodaltons at Thr246) is a biomarker for phosphatidylinositol 3-kinase (PI3K) pathway activation and AKT inhibitors sensitivity.
Material and methods: In this study, we immunohistochemically investigated the expression of phospho-PRAS40Thr246 in 141 gastric cancer tumors, and evaluated its clinicopathological and prognostic significance.
Results: Sixty-four cases (45.4%) were defined as phospho-PRAS40Thr246 positive. Phospho-PRAS40MThr246 correlated positively with lymph node metastasis, lymphatic infiltration, vascular infiltration and shorter survival. Furthermore, phospho-PRAS40Thr246 is an independent prognostic factor for gastric cancer.
Conclusions: Our data suggest that phospho-PRAS40Thr246 was frequently expressed in gastric cancers, and correlated with malignant progression and poor prognosis of patients. PI3K pathway-targeted therapies should be considered in the future treatment of gastric cancers.
Journals System - logo
Scroll to top